Victorian immunologist Prof Suzanne Cory has become the first Australian woman inducted into the French Academy of Sciences. [ + ]

Immune-based therapies developer Virax Holdings (ASX: VHL) has appointed a British scientist to head its vector research and process development. [ + ]

The Amrad Corporation versus Circadian Technologies showdown is set to reach its climax tomorrow when shareholders vote on the future of the board. [ + ]

A group of researchers has identified and cloned the first known gene that makes skin cells able to sense warm temperatures.

Melbourne's Stem Cell Sciences has begun providing pharmaceutical company Aventis with its new test to detect potential Alzheimer's drugs. [ + ]

A small Australian research team believes it is poised to solve a 25-year-old riddle and open new horizons for the global pig industry. [ + ]

The writing was on the wall for the suspension of the Commonwealth government's R&D Start program as early as January, Australian Biotechnology News has learned. [ + ]

Up to $20 million is to be spent setting up Tasmania's Bioinformatics Centre of Excellence, it was announced today. [ + ]

Deputy prime minister and avowed embryonic stem cell research opponent John Anderson has been granted a seat on the government's peak science and innovation council. [ + ]

A team of Japanese and Australian astronomers has found concrete evidence of an elusive component in cosmic rays.

Artificial heart developer MicroMedical Industries has forecast a larger full-year loss than it experienced last year, but said it was an expected outcome. [ + ]

Australians needed to know who was likely to make their fortune through stem cells in order to prioritise information from scientists who may have a vested interest in the research, the Senate has heard. [ + ]

Melbourne bioengineering company Eiffel Technologies has entered a research partnership with London-based Amarin Corporation to manufacture slow-release, sub-micron sized drugs. [ + ]

Two weeks after former Prime Minister Bob Hawke resigned from the board of Autogen, a second director has resigned, citing other business commitments. [ + ]

Meditech Research has completed Phase I clinical trials of its anti-cancer therapy HyDox, indicating the treatment is safe for patients with breast cancer, renal carcinoma, sarcoma and prostate cancer. [ + ]